Wyeth Gets a Couple of FDA Wins (WYE.DL)

Wyeth Gets a Couple of FDA Wins

In a bit of good news for big pharma, Wyeth (NYSE: WYE ) received marketing approval for its second-generation version of its blockbuster antidepressant Effexor on Friday.

The new version of Effexor, named Pristiq, is Wyeth's attempt at extending the sales lifecycle of its Effexor franchise, which begins to face patent expirations this year. Sales of its Effexor franchise were $3.8 billion last year, and it competes against drugs like Forest Labs' (NYSE: FRX ) Lexapro and Pfizer's (NYSE: PFE ) Zoloft, which is available as a generic. Wyeth had been trying to get Pristiq approved since first filing for FDA approval in 2006 and receiving an approvable letter for the drug in early 2007.

Another big FDA win for Wyeth occurred 11 days ago when it received approval for another second-generation product in its hemophilia A treatment Xyntha. Wyeth's already approved hemophilia drug Refacto had sales of $335 million last year and is facing patent expiration in 2010.

Getting second-generation drugs approved to replace their hit predecessor drugs is a mainstay of extending the sales life of many big pharma drugs. This can be an effective strategy when it works, but often fails if private insurers and other payers are unwilling to pay more for the "improved" second-generation product vs. cheaper generic competitors of the first-generation compound.

Only time will tell which category these two Wyeth drugs fit into.

More Foolishness on patent extending drugs:

6 stocks you can't afford to ignore! Motley Fool co-founders David and Tom Gardner just handpicked 6 rock-solid, well-run companies they believe you need to be watching. Get the names and stock symbols right now in a FREE report from The Motley Fool. We'll add the first ticker to your personal My Watchlist, a FREE service that gives you the latest news on the companies that matter most to you. For instant access to your free report, simply enter your email address here:

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.